Veliparib: a new therapeutic option in ovarian cancer?
Future Oncol
; 15(17): 1975-1987, 2019 Jun.
Article
em En
| MEDLINE
| ID: mdl-31074636
ABSTRACT
The role of poly ADP ribose polymerase inhibitors in ovarian cancer is rapidly evolving. Three different poly ADP ribose polymerase inhibitors (olaparib, niraparib and rucaparib) have been already approved as maintenance after response to platinum-based chemotherapy; two of them (olaparib and rucaparib) also as single agents. Veliparib, a novel PARPI, showed promising results in preclinical and early clinical settings. The aim of this review is to discuss veliparib's mechanisms of action, to provide a clinical update on its safety and activity in ovarian cancer, and to highlight future perspectives for its optimal use. Veliparib favorable toxicity profile encourages its use either as monotherapy or in combination. Its peculiar neuroprotective and radio-sensitizing effect warrant further investigation.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Temas:
Geral
/
Tipos_de_cancer
/
Outros_tipos
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Benzimidazóis
/
Reparo do DNA
/
Inibidores de Poli(ADP-Ribose) Polimerases
Limite:
Female
/
Humans
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Itália